Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Lucentis

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Lucentis was produced by Novartis and Roche.

NICE no for new eye disease drug

NICE no for new eye disease drug drugs on the market, including Novartis/Roche's Lucentis (ranibizumab) and Bayer/Regeneron's Eylea (aflibercept).

Eylea growth closes the gap with Lucentis

Eylea growth closes the gap with Lucentis Armed with new indications such as diabetic macular edema (DME), Eylea (aflibercept) can now compete with rival Lucentis (ranibizumab) sold by Roche and Novartis on a more equal footing and sales ... Lucentis still selling more than Eylea by value but is

Medius Deal Watch table for February 2015

Medius Deal Watch table for February 2015 Majority acquisition. 380. Pfenex/ Hospira. PF582 -  LUCENTIS biosimilar candidate - wet age-related macular degeneration, diabetic macular oedema.

Roche maintains top place in biologic sales

Roche maintains top place in biologic sales It also has a strong showing from across its drug portfolio, with its breast cancer drug Herceptin (trastuzumab) bringing in more than CHF6bn last year, with eye drug Lucentis (ranibizumab) and

Trials of Roche's new blindness candidate now underway

Trials of Roche's new blindness candidate now underway Roche and partner Novartis already market their vascular endothelial growth factor (VEGF) inhibitor Lucentis (ranibizumab) for the wet or neovascular form of AMD, as well as macular oedema caused by diabetes ... While multiple therapies exist for wet

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics